• Something wrong with this record ?

The efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes

E. Bonifacio, R. Coelho, DA. Ewald, G. Gemulla, M. Hubmann, P. Jarosz-Chobot, M. Kohls, O. Kordonouri, V. Lampasona, P. Narendran, F. Pociot, Z. Šumník, A. Szypowska, J. Zapardiel-Gonzalo, AG. Ziegler

. 2025 ; 68 (6) : 1101-1107. [pub] 20250319

Language English Country Germany

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25015530

Grant support
G-2103-05036 Leona M. and Harry B. Helmsley Charitable Trust
FZK 01KX1818 Bundesministerium für Bildung und Forschung
grant agreement No 101132379 Innovative Health Initiative

Early detection of type 1 diabetes, in its presymptomatic stage, offers significant clinical advantages, including treatment that can delay disease onset. Current screening focuses on identifying islet autoantibody positivity, with proposed optimal testing at ages 2, 6 and 10 years potentially achieving up to 80% sensitivity. However, challenges arise from participation rates and costs associated with multiple screenings. Genetic pre-screening has been suggested as a complementary strategy to target high-risk individuals prior to autoantibody testing, but its real-world benefits remain uncertain. Broad genetic selection strategies, based on family history, HLA typing or polygenic risk scores, can identify subsets of the population at elevated risk. However, these approaches face issues like low recall rates, socioeconomic biases and limited applicability across diverse ancestries. Additionally, the cost-effectiveness and infrastructure requirements of integrating genetic testing into routine healthcare remain significant hurdles. The combined use of genetic and autoantibody testing could improve predictive value, especially with innovations like point-of-care genetic testing. Yet, the ultimate success of any screening programme depends less on specific strategies and more on maximising public and healthcare-provider engagement, ensuring high participation, and addressing socioeconomic and demographic disparities. Digital-health infrastructure may play a crucial role in improving recall rates and maintaining follow-up adherence. In conclusion, while repeated islet autoantibody screening remains the most effective standalone approach, conducting genetic screening prior to islet autoantibody testing may be practical in certain contexts, provided that sufficient resources and equitable strategies are employed. Public engagement and robust infrastructure are essential to realising the full potential of early type 1 diabetes detection programmes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015530
003      
CZ-PrNML
005      
20250731091042.0
007      
ta
008      
250708s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00125-025-06408-4 $2 doi
035    __
$a (PubMed)40105972
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Bonifacio, Ezio $u Center for Regenerative Therapies Dresden, Faculty of Medicine, TU Dresden, Dresden, Germany. ezio.bonifacio@tu-dresden.de $1 https://orcid.org/0000000287044713
245    14
$a The efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes / $c E. Bonifacio, R. Coelho, DA. Ewald, G. Gemulla, M. Hubmann, P. Jarosz-Chobot, M. Kohls, O. Kordonouri, V. Lampasona, P. Narendran, F. Pociot, Z. Šumník, A. Szypowska, J. Zapardiel-Gonzalo, AG. Ziegler
520    9_
$a Early detection of type 1 diabetes, in its presymptomatic stage, offers significant clinical advantages, including treatment that can delay disease onset. Current screening focuses on identifying islet autoantibody positivity, with proposed optimal testing at ages 2, 6 and 10 years potentially achieving up to 80% sensitivity. However, challenges arise from participation rates and costs associated with multiple screenings. Genetic pre-screening has been suggested as a complementary strategy to target high-risk individuals prior to autoantibody testing, but its real-world benefits remain uncertain. Broad genetic selection strategies, based on family history, HLA typing or polygenic risk scores, can identify subsets of the population at elevated risk. However, these approaches face issues like low recall rates, socioeconomic biases and limited applicability across diverse ancestries. Additionally, the cost-effectiveness and infrastructure requirements of integrating genetic testing into routine healthcare remain significant hurdles. The combined use of genetic and autoantibody testing could improve predictive value, especially with innovations like point-of-care genetic testing. Yet, the ultimate success of any screening programme depends less on specific strategies and more on maximising public and healthcare-provider engagement, ensuring high participation, and addressing socioeconomic and demographic disparities. Digital-health infrastructure may play a crucial role in improving recall rates and maintaining follow-up adherence. In conclusion, while repeated islet autoantibody screening remains the most effective standalone approach, conducting genetic screening prior to islet autoantibody testing may be practical in certain contexts, provided that sufficient resources and equitable strategies are employed. Public engagement and robust infrastructure are essential to realising the full potential of early type 1 diabetes detection programmes.
650    _2
$a lidé $7 D006801
650    12
$a autoprotilátky $x imunologie $7 D001323
650    12
$a diabetes mellitus 1. typu $x diagnóza $x genetika $x imunologie $7 D003922
650    12
$a genetické testování $x metody $7 D005820
650    12
$a Langerhansovy ostrůvky $x imunologie $7 D007515
650    _2
$a plošný screening $x metody $7 D008403
655    _2
$a časopisecké články $7 D016428
700    1_
$a Coelho, Raquel $u Pediatric Department, APDP-Diabetes Portugal, Education and Research Center (APDP-ERC), Lisboa, Portugal $1 https://orcid.org/000000029325088X
700    1_
$a Ewald, Domenik A $u Practice for Paediatric Medicine, Regensburg, Germany
700    1_
$a Gemulla, Gita $u Department of Paediatrics, University Hospital Carl Gustav Carus, Dresden, Germany $1 https://orcid.org/0009000178432669
700    1_
$a Hubmann, Michael $u Practice for Paediatric Medicine, Zirndorf, Germany
700    1_
$a Jarosz-Chobot, Przemyslawa $u Department of Children's Diabetology and Lifestyle Medicine, Medical University of Silesia, Katowice, Poland $1 https://orcid.org/0000000211200994
700    1_
$a Kohls, Mirjam $u Institute of Diabetes Research, Helmholtz Munich, Munich, Germany $1 https://orcid.org/0000000349437791
700    1_
$a Kordonouri, Olga $u Department of Pediatrics, Diabetology, Endocrinology, and Clinical Research, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany $1 https://orcid.org/0000000195633537
700    1_
$a Lampasona, Vito $u Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy $1 https://orcid.org/0000000151628445
700    1_
$a Narendran, Parth $u Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK $1 https://orcid.org/0000000245838793
700    1_
$a Pociot, Flemming $u Clinical and Translational Research, Steno Diabetes Center Copenhagen, Herlev, Denmark $1 https://orcid.org/0000000332745448
700    1_
$a Šumník, Zdenek $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czechia $1 https://orcid.org/0000000264626462 $7 xx0036973
700    1_
$a Szypowska, Agnieszka $u Department of Paediatric Diabetology and Paediatrics, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000234073174
700    1_
$a Zapardiel-Gonzalo, Jose $u Institute of Diabetes Research, Helmholtz Munich, Munich, Germany $1 https://orcid.org/0000000290981652
700    1_
$a Ziegler, Anette-Gabriele $u Institute of Diabetes Research, Helmholtz Munich, Munich, Germany $1 https://orcid.org/0000000262905548
773    0_
$w MED00001391 $t Diabetologia (Berlin) $x 1432-0428 $g Roč. 68, č. 6 (2025), s. 1101-1107
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40105972 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091037 $b ABA008
999    __
$a ok $b bmc $g 2366399 $s 1252655
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 68 $c 6 $d 1101-1107 $e 20250319 $i 1432-0428 $m Diabetologia (Berlin) $n Diabetologia $x MED00001391
GRA    __
$a G-2103-05036 $p Leona M. and Harry B. Helmsley Charitable Trust
GRA    __
$a FZK 01KX1818 $p Bundesministerium für Bildung und Forschung
GRA    __
$a grant agreement No 101132379 $p Innovative Health Initiative
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options